Physician profile
Christopher John Borgiel
NPI 1316914245
$11,320.77
in general payments reported to CMS, 2019-2025
41 companies · $2,127 in 2025
The $2,127 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $715 · 2021: $1,771 · 2022: $1,576 · 2023: $1,820 · 2024: $1,931 · 2025: $2,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,877.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,540.05 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,455.12 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,289.70 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,082.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $477.93 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $459.74 | 2019-2025 | Repatha, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $377.15 | 2023-2025 | Rexulti |
| Pfizer INC. | $366.40 | 2019-2025 | |
| Amarin Pharma, INC. | $343.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $337.88 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $337.26 | 2019-2025 | Spravato |
| Paratek Pharmaceuticals, INC. | $265.20 | 2022-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $257.40 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $246.97 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.04 | 2022-2025 | Caplyta |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Borgiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.